Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duloxetine Approved In EU For Stress Urinary Incontinence

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly and marketing partner Boehringer Ingelheim plan to launch duloxetine under the trade name Yentreve by year-end in the European Union. The NDA for Yentreve is pending at FDA.

You may also be interested in...



Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review

Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.

Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review

Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.

Cymbalta Approved; Lilly Antidepressant Will Be Available By Late August

Cymbalta (duloxetine) clears FDA for major depressive disorder after a lengthy review. It will be priced comparably to other antidepressants, including Wyeth's Effexor XR (venlafaxine), the other marketed selective serotonin/norepinephrine reuptake inhibitor.

Topics

UsernamePublicRestriction

Register

PS060287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel